The original Signal Transduction (ST) Program Area was established in 1997 to bring together researchers Studying a variety of signaling pathways, including pathways initiated by receptors and membrane-mediated events, heterotrimeric G-protein, small G-protein- and protein kinase-mediated intermediate signaling events, and distal transcription factor activation. The ST Program Area sponsored large symposia to promote discussion and to facilitate interaction among ST researchers. Research during this period led to the identification of molecular targets, which then led to the development of signal transduction inhibitors. Because of the translational potential of signal transduction research for cancer therapy, we wanted to create a platform where basic scientists could discuss their studies on signaling pathways with clinicians carrying out clinical trials of signal transduction inhibitors. To create this platform, the ST Program Area was reconfigured in 2007 as the Signal Transduction and Therapeutics (STT) Program Area. The new/revised STT Program Area includes both basic scientists and clinicians.
Our aim i s to have an easy, transparent transition from basic science to the clinic and from the clinic to basic science. During the current funding period, basic science and clinical activities in the STT Program Area have truly become integrated. Our members share a passion to promote new cancer therapies based on basic signal transduction observations. We promote translational aspects of our Program Area by holding meetings and seminars that gather basic scientists and clinicians, who exchange their experience and knowledge on signaling pathways of common interest. The STT Program Area is comprised of 47 members, including four

Public Health Relevance

): Most targeted cancer therapeutics that have been developed to date inhibit specific signaling pathways required for the growth of cancer cells. The Signal Transduction and Therapeutics Program Area brings together basic, translational, and clinical researchers to optimize and speed the development of novel therapeutics that target signaling pathways.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635436
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$28,196
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Law, Ivy Ka Man; Jensen, Dane; Bunnett, Nigel W et al. (2016) Neurotensin-induced miR-133α expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep 6:22195
Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40
Palanichamy, Jayanth Kumar; Tran, Tiffany M; Howard, Jonathan M et al. (2016) RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest 126:1495-511
Van Dyk, Kathleen; Ganz, Patricia A; Ercoli, Linda et al. (2016) Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer 24:4939-4949
Bostean, Georgiana; Crespi, Catherine M; Vorapharuek, Patsornkarn et al. (2016) E-cigarette use among students and e-cigarette specialty retailer presence near schools. Health Place 42:129-136
Aguilera-Sandoval, Christian R; Yang, Otto O; Jojic, Nebojsa et al. (2016) Supranormal thymic output up to 2 decades after HIV-1 infection. AIDS 30:701-11
Bauer, Margaret R; Harris, Lauren N; Wiley, Joshua F et al. (2016) Dispositional and Situational Avoidance and Approach as Predictors of Physical Symptom Bother Following Breast Cancer Diagnosis. Ann Behav Med 50:370-84
Horvath, Steve; Gurven, Michael; Levine, Morgan E et al. (2016) An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol 17:171
Ganz, Patricia A; Petersen, Laura; Bower, Julienne E et al. (2016) Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 34:816-24
Dooley, Larissa N; Ganz, Patricia A; Cole, Steve W et al. (2016) Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord 197:43-50

Showing the most recent 10 out of 568 publications